Regeneron Pharmaceuticals Inc (REGN) Stock Analysis
Verdict: WATCH (do not buy)
Regeneron’s oncology pipeline failure creates a valuation-entry opportunity masked by technical damage and overblown growth-pivot fears.
Investment score: 58/100
Analysis as of
Is Regeneron Pharmaceuticals Inc stock worth reviewing? AI model thesis
Regeneron is trading at a significant discount to peers despite better margins and lower debt, following a recent Phase 3 failure.
7-factor investment score
- Valuation: 78/100 (weight 20%)
- Financial Health: 85/100 (weight 15%)
- Technical Momentum: 20/100 (weight 15%)
- Earnings Quality: 90/100 (weight 15%)
- Insider Sentiment: 25/100 (weight 10%)
- Analyst Consensus: 70/100 (weight 10%)
- Risk-Adjusted Return: 50/100 (weight 15%)
Regeneron Pharmaceuticals Inc opportunities and risks
What speaks for REGN
- Deep Valuation Discount
What speaks against REGN
- Oncology Pipeline Sentiment Contagion
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| REGN | 14.8x | 4.3x | 11.2x | 84.5% | 29.6% | 6.4% |
| ABBV | 102.1x | 5.9x | 24.1x | 73.5% | 5.8% | 5.6% |
| AMGN | 22.5x | 4.7x | 12.7x | 71.5% | 20.9% | 4.9% |
| GILD | 17.5x | 5.4x | 13.2x | 79.4% | 31.0% | 6.4% |
| VRTX | 25.6x | 9.0x | 20.7x | 86.3% | 35.4% | 3.3% |
| Peer median | 24.0x | 5.7x | 16.9x | 76.4% | 26.0% | 5.3% |
Frequently asked questions about Regeneron Pharmaceuticals Inc (REGN)
Is REGN stock a good investment?
The cached TradeMates AI model rates Regeneron Pharmaceuticals Inc as WATCH (do not buy) with an investment score of 58/100. Regeneron is trading at a significant discount to peers despite better margins and lower debt, following a recent Phase 3 failure. This is algorithmic model output, not personal investment advice.
Is REGN stock a buy?
The TradeMates model verdict for REGN is WATCH (do not buy) with an investment score of 58/100. Treat this as a model signal to review, not a personal buy recommendation.